Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594673 | 0.92 | CYP2A6 (0.39) | CYP2A6CA2ALDH1A1CA12CA3 | |
| SCHEMBL3686725 | 0.82 | — | — | |
| SCHEMBL31336299 | 0.80 | HRH3 (0.43) | CYP2A6ALDH1A1HRH3HRH2HRH1 | |
| SCHEMBL6826037 | 0.78 | ENPP2 (0.37) | ALDH1A1TSHRMAOBENPP2PDE4A | |
| SCHEMBL14985961 | 0.76 | CA2 (0.44) | CYP2A6CA2ALDH1A1CA12CA3 | |
| SCHEMBL5891951 | 0.76 | POLB (0.39) | CYP2A6CA2ALDH1A1CA12CA3 | |
| SCHEMBL6828850 | 0.72 | LPL (0.42) | — | |
| SCHEMBL7590626 | 0.72 | CYP2A6 (0.36) | CYP2A6 | |
| SCHEMBL16876888 | 0.72 | — | — | |
| SCHEMBL7591877 | 0.72 | ACHE (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8945820-B2 | Silicon-containing resist underlayer film-forming composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20130137271-A1 | SILICON-CONTAINING RESIST UNDERLAYER FILM-FORMING COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-7297702-B2 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-11-20 | — | — | US | disclosed |
| US-20050026885-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-02-03 | — | — | US | disclosed |
| US-6790853-B2 | SIDE EFFECT REDUCTION; HORMONE INHIBITOR | SCHERING AG (DE) | 2004-09-14 | — | — | US | disclosed |
| US-20030191102-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | SCHERING AG (DE) | 2003-10-09 | — | — | US | disclosed |
| US-6608074-B2 | Administering during follicular phase of female menstrual cycle and in luteal phase, a competitive progesterone antagonist, which is less than an ovulation-inhibiting dose and less than an abortion-inductive dose | SCHERING AG (DE) | 2003-08-19 | — | — | US | disclosed |
| EP-0639970-B2 | CONTRACEPTION METHOD USING COMPETITIVE PROGESTERONE ANTAGONISTS AND NOVEL COMPOUNDS USEFUL THEREIN | SCHERING AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-0675118-B1 | Biphenylderivatives, process for their preparation and their use as medicaments | EISAI CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-20020058649-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | SCHERING AG (DE) | 2002-05-16 | — | — | US | disclosed |
| US-6340688-B1 | ADMINISTERING TO FEMALE DURING MENSTRUAL CYCLE AMOUNT OF COMPETITIVE PROGESTERONE ANTAGONIST WHICH IS LESS THAN OVULATION-INHIBITING DOSE AND LESS THAN ABORTION-INDUCTIVE DOSE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-22 | — | — | US | disclosed |
| US-6281214-B1 | USEFUL FOR TREATING AND AMELIORATING MENTAL DISORDERS | EISAI CO., LTD (JP) | 2001-08-28 | — | — | US | disclosed |
| EP-0639970-B1 | CONTRACEPTION METHOD USING COMPETITIVE PROGESTERONE ANTAGONISTS AND NOVEL COMPOUNDS USEFUL THEREIN | SCHERING AG (DE) | 1998-01-28 | — | — | EP | disclosed |
| EP-0675118-A2 | Biphenylderivatives, process for their preparation and their use as medicaments | Eisai Co., Ltd. (JP) | 1995-10-04 | — | — | EP | disclosed |
| US-5439913-A | 11B,19-(4-(Cyanophenyl)-o-phenylene)-17B-hydroxy-17a-(3-hydroxyprop -1(Z)-enyl)-4-androsten-3-one or 11B,19-(4-(3-pyridinyl)-o-phenylene)-17B-hydroxy-17a-(3-hydroxyprop-1(Z) -enyl)-4-androsten-3-one | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | disclosed |
| EP-0639970-A1 | CONTRACEPTION METHOD USING COMPETITIVE PROGESTERONE ANTAGONISTS AND NOVEL COMPOUNDS USEFUL THEREIN | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023020-A1 | CONTRACEPTION METHOD USING COMPETITIVE PROGESTERONE ANTAGONISTS AND NOVEL COMPOUNDS USEFUL THEREIN | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026885-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | PGR, PGRMC1, HSD17B11 | CYP2A6 99/4885CA2 4531/4885ALDH1A1 1039/4885 |
| US-20020058649-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | PGR, PGRMC1, PGRMC2 | CYP2A6 82/4885CA2 4416/4885ALDH1A1 1647/4885 |
| US-20030191102-A1 | Contraception method using competitive progesterone antagonists and novel compounds useful therein | PGR, PGRMC1, PGRMC2 | CYP2A6 82/4885CA2 4416/4885ALDH1A1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.